Niko A Kemi1, Maarit Eskuri1, Vesa-Matti Pohjanen1, Tuomo J Karttunen1, Joonas H Kauppila1,2. 1. Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland. 2. Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Abstract
AIMS: Histological assessment of stromal maturity is a potential prognostic factor in colorectal cancer, but its applicability in gastric adenocarcinoma is completely unknown. The aim of this study was to evaluate the feasibility and prognostic significance of assessing stromal maturity in gastric adenocarcinoma. METHODS AND RESULTS: This study was conducted retrospectively in a cohort of 583 gastric adenocarcinoma patients treated surgically in Oulu University Hospital, Finland between 1983 and 2016. The original diagnostic slides were used for assessment of stromal maturity. Patients were divided into mature stroma and immature stroma groups, and stromal maturity was analysed in relation to 5-year and overall survival (OS). The primary outcome of the study was 5-year survival, and the secondary outcome was OS. The kappa-coefficient for interobserver agreement was 0.609. Patients with immature stroma had worse 5-year survival compared to patients with mature stroma [adjusted hazard ratio (HR) = 1.32, 95% confidence interval (CI) = 1.06-1.64]. Stromal maturity was significantly associated with 5-year survival in intestinal-type subgroup (adjusted HR = 0.63, 95% CI = 1.20-2.21), but not in the diffuse-type subgroup (adjusted HR = 1.21, 95% CI = 0.87-1.70). CONCLUSIONS: Stromal maturity is an independent prognostic factor in gastric adenocarcinoma, and it can be analysed with moderate reproducibility.
AIMS: Histological assessment of stromal maturity is a potential prognostic factor in colorectal cancer, but its applicability in gastric adenocarcinoma is completely unknown. The aim of this study was to evaluate the feasibility and prognostic significance of assessing stromal maturity in gastric adenocarcinoma. METHODS AND RESULTS: This study was conducted retrospectively in a cohort of 583 gastric adenocarcinomapatients treated surgically in Oulu University Hospital, Finland between 1983 and 2016. The original diagnostic slides were used for assessment of stromal maturity. Patients were divided into mature stroma and immature stroma groups, and stromal maturity was analysed in relation to 5-year and overall survival (OS). The primary outcome of the study was 5-year survival, and the secondary outcome was OS. The kappa-coefficient for interobserver agreement was 0.609. Patients with immature stroma had worse 5-year survival compared to patients with mature stroma [adjusted hazard ratio (HR) = 1.32, 95% confidence interval (CI) = 1.06-1.64]. Stromal maturity was significantly associated with 5-year survival in intestinal-type subgroup (adjusted HR = 0.63, 95% CI = 1.20-2.21), but not in the diffuse-type subgroup (adjusted HR = 1.21, 95% CI = 0.87-1.70). CONCLUSIONS: Stromal maturity is an independent prognostic factor in gastric adenocarcinoma, and it can be analysed with moderate reproducibility.
Authors: Joonas H Kauppila; Pasi Ohtonen; Tuomo Rantanen; Tuula Tyrväinen; Vesa Toikkanen; Minna Pääaho; Antti Valtola; Jari Räsänen; Raija Kallio; Eero Sihvo; Juha Saarnio; Tuomo J Karttunen; Vesa-Matti Pohjanen; Ari Ristimäki; Simo Laine; Arto Kokkola Journal: BMJ Open Date: 2020-10-16 Impact factor: 2.692